• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

    2/14/24 4:50:00 PM ET
    $BLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLPH alert in real time by email
    SC 13G/A 1 d728319dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Bellerophon Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    078771300

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 078771300

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 078771300

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 078771300

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    Bellerophon Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101, Foxborough, MA 02035

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.01 par value per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    078771300

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 12,232,648 shares of Common Stock outstanding as reported by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023.


    The Master Fund directly holds 0 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own shares held by the Master Fund.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    /s/ Joseph Edelman
    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member
    Get the next $BLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

      WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. "The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® de

      5/11/23 8:30:42 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

      Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater ChinaStrengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022. "We have achieved significant recent pro

      3/31/23 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

      WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. "We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "Our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension is progressing well and con

      8/5/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

      WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of

      5/26/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Financials

    Live finance-specific insights

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BLPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Puissance Capital Management Lp sold $111,776 worth of shares (1,076,841 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      10/16/23 8:51:41 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Amin Naseem

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:24 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fernandes Peter

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:06 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:50:00 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:00:25 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bellerophon Therapeutics Inc.

      SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      1/26/24 10:46:43 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    SEC Filings

    See more
    • Bellerophon Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      3/4/24 5:25:30 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 3:44:59 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 12:39:17 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care